A retired UCLA professor told doctors would last only months after a rare pancreatic cancer diagnosis has now survived 14 years, helped by surgery and a targeted therapy cleared before his relapse.
Federico Kalinec was diagnosed in 2012 with a pancreatic neuroendocrine tumor, a rare form of the disease that also claimed Apple co-founder Steve Jobs a year earlier. Doctors gave him two to three months. He is still here.
Daily Mail reporting on his case lays out a long fight: major surgery that bought him years, a 2020 relapse, and peptide receptor radionuclide therapy, a radioactive drug treatment the FDA had approved in 2018 for these uncommon tumors.
“I was given originally two months, three months to live, and it's already been 14 years,” Kalinec said.
"I was given originally two months, three months to live, and it's already been 14 years,"
He put the attitude plain in another line from the same interview.
"I have cancer, but I don't give up and we are fighting,"
Pancreatic neuroendocrine tumors, often grouped with related gut tumors as GEP-NETs, are uncommon. An FDA press release cited in the coverage put the figure at roughly one diagnosis per 27,000 people each year.
That rarity does not make the disease gentle. Kalinec presented with jaundice and cancer that had already spread to multiple organs. Surgeons removed his pancreas and part of his stomach. The operation contained the disease for years.
Steve Jobs died in 2011 at 56 from the same rare strain. Kalinec’s 2012 diagnosis came with the short clock patients dread. He beat it the hard way, through resection first, then a newer option when the cancer came back.
In 2018 the Food and Drug Administration approved a new treatment path for certain gastric and pancreatic tumors, including the peptide receptor radionuclide therapy approach later used in cases like his.
Richard Pazdur, M.D., of the FDA framed the decision in straightforward terms in the agency’s announcement.
"This approval provides another treatment choice for patients with these rare cancers."
For patients who relapse after surgery, another choice is not a slogan. It is the difference between watching a tumor run and hitting it with a tool built for that cell type.
Peptide receptor radionuclide therapy, known as PRRT, is a highly targeted regimen. The Society of Nuclear Medicine and Molecular Imaging describes it as a series of injections given over a four- to five-hour period.
The point is precision. A radioactive drug homes in on tumor cells rather than soaking the whole body in the blunt style of older regimens. Listed benefits include symptom relief and a slowing of tumor growth.
Dr. Timothy Donahue explained the mechanism in comments carried with Kalinec’s story.
"It targets those tumor cells and kills them directly. And that's been shown to be very effective for pancreatic neuroendocrine tumors."
Kalinec’s disease returned in 2020. By then the 2018 approval was on the books. The sequence mattered: surgery first, regulatory clearance in the middle years, relapse later, and a therapy ready when he needed the next move.
The timeline is simple and hard to argue with. Diagnosis in 2012. Pancreas and partial stomach removed soon after. FDA approval of the newer option in 2018. Relapse in 2020. An interview years on in which the patient could say the original two-to-three-month forecast was already 14 years behind him.
UCLA ties run through the account, Kalinec is a retired professor there, and the coverage framed the care in that cutting-edge setting, though the public file does not pin every procedure to a single hospital campus for a national reader.
What the record does show is a man who refused the first deadline, accepted major surgery, and used a post-2018 therapy when the cancer reappeared. Jobs’s death from the same rare cancer remains the grim public marker of how fast this disease can move. Kalinec’s arc is the counterexample built on knives, timing, and a drug that seeks the tumor itself.
GEP-NETs stay rare. One in 27,000 a year is not a mass-market crisis, which is exactly why targeted approvals matter. Large trials and broad political attention chase common cancers. Uncommon ones need regulators willing to clear real options and clinicians willing to use them.
Pazdur’s line was not poetry. It was an admission that patients in this niche needed another tool. Donahue’s description matches that purpose: bind the tumor, kill those cells, slow the march.
Kalinec’s own words do the rest. He does not claim a cure in the material on record. He claims time he was not supposed to have, and a refusal to quit while treatment still had a shot.
When medicine clears a precise weapon and a patient has the will to use every year it buys, rare cancers stop writing the ending alone, grit and working innovation still get a vote.
